ETV1 and prostate cancer: Since the anti-tumor efficacy of YK-4-279 in Ewing’s sarcoma was demonstrated in 2009, ERG/ETV1-mediated prostate cancer and EWS-FLI1-induced leukemia have been verified as additional target diseases [14–21].